Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
Immune checkpoint inhibitors (ICIs) are highly concerned in the treatment of non-small cell lung cancer (NSCLC), represented by inhibitors of programmed death protein 1 (PD-1) and its ligand (PD-L1), and inhibitors of cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). The introduction of immunoth...
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | 論文 |
| 言語: | English |
| 出版事項: |
Frontiers Media S.A.
2023-01-01
|
| シリーズ: | Frontiers in Oncology |
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1099304/full |